Why is "Abacavir" trending?

Search Interest Perspective

• Stopping abacavir not linked to weight gain in HIV care - European AIDS Treatment Group
• Abacavir enhances the efficacy of doxorubicin via inhibition of histone demethylase KDM5B in breast cancer - Nature
• Lupin Receives Approval from U.S. FDA for Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension - lupin.com
• Abacavir-based ART regimens linked to higher MACE risk in patients with HIV - European AIDS Treatment Group
• Exploratory analysis associates HIV drug abacavir with elevated cardiovascular disease risk in large global trial - National Institutes of Health (.gov)
• Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy - NEJM
• Large international study finds 40% higher risk of serious cardiovascular problems in people taking abacavir since 2012 - Aidsmap
• Study Finds Abacavir Increases Cardiovascular Risk in Patients With HIV - Pharmacy Times
• Accelerating access to better medicines for children: Ensuring successful introduction of paediatric abacavir/lamivudine/dolutegravir (pALD) fixed-dose combination and sustainability of pDTG - World Health Organization (WHO)
• Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire - PNAS
• Antiretroviral abacavir linked with cardiovascular events in REPRIEVE trial - University of Cincinnati
• The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome - Nature
• Lupin launches Generic Epzicom® tablets in the US - Lupin | Press Release - lupin.com
• Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection - NEJM
• Switching from abacavir to TAF improves platelet function - Aidsmap
• Antiretroviral abacavir linked with cardiovascular events in REPRIEVE trial - European AIDS Treatment Group
• Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors - Nature
• Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection - NEJM
• HLA-B*5701 Screening for Hypersensitivity to Abacavir - NEJM
• Abacavir hypersensitivity: a model system for pharmacogenetic test adoption - Nature
• EACS 2021: Abacavir still causing serious cardiovascular problems, Friday 29 October 2021 - Aidsmap
• NIH-funded trial finds abacavir linked to higher cardiovascular risk - Clinical Trials Arena
• Predisposition to abacavir hypersensitivity conferred by HLA-B 5701 and a haplotypic Hsp70-Hom variant - PNAS
• Abacavir use is associated with increased prothrombin conversion - Frontiers
• Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial - The Lancet
• Immune self-reactivity triggered by drug-modified HLA-peptide repertoire - Nature
• Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study - The Lancet
• Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity - Nature
• Dolutegravir and central nervous system side-effects: abacavir, older age increase the risk - Aidsmap
• Biktarvy Found to Be Non-Inferior to Abacavir-Containing Regimen in Phase 3 Study - Medical Professionals Reference
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration - The Lancet
• Exploratory Analysis Associates HIV Drug Abacavir With Elevated Cardiovascular Disease Risk - poz.com
• High levels of infant resistance to abacavir and tenofovir in Namibia - Aidsmap
• Another signal of concern with abacavir and cardiovascular risk - CATIE.ca
• FDA provides tentative approval for HIV therapy for children - European AIDS Treatment Group
• Heart attack link to abacavir persists in D:A:D study - Aidsmap
• Monitoring abacavir bioactivation in humans: Screening for an aldehyde metabolite - ScienceDirect.com
• Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility - Nature
• New approaches for paediatric dosing: abacavir in newborns, doubling dolutegravir with rifampicin - Aidsmap
• Abacavir Cardiovascular Disease Risk - Infectious Disease Special Edition
• US: Department of Health and Human Services updates HIV guidelines - European AIDS Treatment Group
• Lupin Receives Approval from U.S. FDA for Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension - lupin.com
• Kidney problems linked to tenofovir use, improve with switch to abacavir - Aidsmap
• Discontinuation of Several HIV Medications Reported to FDA - Medical Professionals Reference
• Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity - PLOS
• Triumeq (dolutegravir/abacavir/lamivudine) for the Treatment of HIV - Clinical Trials Arena
• Triumeq for HIV: Dosage, Side Effects, and More - TheBody
• Drug-Drug Interaction of Ergotamine with a Combination of Darunavir, Abacavir, and Lamivudine Causing a Fatal Vasospastic Ischemia - Wiley Online Library
• FDA Grants Tentative Approval of Triumeq PD Generic for Children with HIV - Managed Healthcare Executive
• More evidence that older version of tenofovir protects against severe COVID – in people over 50 - Aidsmap
• New Combo Tablets Approved for HIV-1 Infection - Medical Professionals Reference
• DHHS Updates HIV Guidelines - poz.com
• (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection - MultiVu
• 5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir - The Lancet
• ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children - GSK
• Teva Launches Generic Epzicom - Medical Professionals Reference
• FDA Gives Tentative Clearance to Viatris’ HIV Treatment for Children - Pharmaceutical Executive
• WHO and United States Food and Drug Administration extend the CRP-Lite pilot - World Health Organization (WHO)
• Abacavir and Tenofovir Associated With Heart Troubles - poz.com
• Kenya's HIV drug combo is safe from resistance - report - the-star.co.ke
• Triumeq: Side effects, cost, dosage, uses, and more - Medical News Today
• Lupin gains USFDA approval for Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension - Express Pharma
• Blood tests before starting or changing HIV treatment - Aidsmap
• The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial - The Lancet
• Switching Off Ziagen Is Linked to Healthier Platelets in People With HIV - poz.com
• Exploring weight changes with different integrase inhibitors - CATIE.ca
• Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01 - Nature
• Avoiding severe drug hypersensitivity reactions: a case for HLA genotyping for at‐risk patients - The Medical Journal of Australia
• Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- But Really 2 Are Best - NEJM
• Morning Dosing of Tivicay May Ease Insomnia Side Effect - poz.com
• Combination ABC/3TC/DTG Approved — Fourth One Pill a Day HIV Treatment - NEJM
• Teva Canada Announces the Launch of (Pr)Teva-Abacavir/Lamivudine Tablets, a Generic of (Pr)Kivexa® - Newswire Canada
• Test Detects Sensitivity to HIV Drug - ABC News
• ARV stockouts putting lives at risk, says SSP - spotlightnsp.co.za
• Taking Dolutegravir in the Morning Can Prevent Insomnia - Life4me+
• No HIV patient on treatment affected by shortage of antiretrov­iral medication - PressReader
• Ghana warned of shortage of HIV anti-retroviral drugs for patients - MyJoyOnline
• Brexit transport issues cause further HIV medicine delay, authorities say - Times of Malta
• Ghana grappling with severe shortage of AVR drugs - NewsGhana